Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMRJQ8X)

• Drug Name: D-Pro-Phe-Arg chloromethyl ketone Drug Info
• Synonyms: H-D-Pro-Phe-Arg-chloromethylketone; 88546-74-1; CHEMBL521527; BDBM23569; CTK8G0139; DTXSID90440219; ZINC13507825; D-Pro-Phe-Arg chloromethyl ketone (PCK); (R)-N-((S)-1-((S)-1-chloro-6-guanidino-2-oxohexan-3-ylamino)-1-oxo-3-phenylpropan-2-yl)pyrrolidine-2-carboxamide

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 10456438
  CAS Number: CAS 88546-74-1
  TTD Drug ID: DMRJQ8X

Molecule-Related Drug Atlas

Drug(s) Targeting Tissue factor (F3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tisotumab vedotin	DMF8FK3	Cervical cancer	2C77.0	Approved	[2]
ALT-836	DMGJ71F	Adult respiratory distress syndrome	CB00	Phase 2	[3]
TT-173	DMSIXG4	Bleeding disorder	GA20-GA21	Phase 2	[4]
MORAb-066	DMTUKW9	Pancreatic cancer	2C10	Phase 1	[5]

Drug(s) Targeting Plasma kallikrein (KLKB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ecallantide	DMOF2C6	Retina venous occlusion	9B74.1	Approved	[6]
Lanadelumab	DMEH7YU	Hereditary angioedema	4A00.14	Approved	[7]
Berotralstat	DMWA2DZ	Hereditary angioedema	4A00.14	Approved	[8]
KVD001	DMK4VOU	Diabetic macular edema	9B71.02	Phase 2	[9]
KVD824	DM5N4OA	Diabetic macular edema	9B71.02	Phase 2	[10]
THR-149	DMW8X05	Diabetic macular edema	9B71.02	Phase 2	[11]
(4-bromo-1H-pyrazol-1-yl)(p-tolyl)methanone	DM31OSD	Discovery agent	N.A.	Investigative	[12]
(3-nitro-1H-pyrazol-1-yl)(p-tolyl)methanone	DMT9FZD	Discovery agent	N.A.	Investigative	[12]
1-benzoyl-N-phenyl-1H-pyrazole-3-carboxamide	DMG5MNZ	Discovery agent	N.A.	Investigative	[12]
(3,4-dichlorophenyl)(1H-pyrazol-1-yl)methanone	DMNVDLI	Discovery agent	N.A.	Investigative	[12]

Drug(s) Targeting Coagulation factor Xa (F10)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Apixaban	DM89JLN	Thrombosis	DB61-GB90	Approved	[13]
Rivaroxaban	DMQMBZ1	Deep vein thrombosis	BD71	Approved	[14]
DU-176b	DMCIJBH	Atrial fibrillation	BC81.3	Approved	[15]
Emicizumab	DM0AQ83	Factor VIII deficiency	3B10	Approved	[16]
BETRIXABAN	DM2C4RF	Venous thromboembolism	BD72	Approved	[17]
Lmw heparin	DMJPD06	Coagulation defect	3B10.0	Approved	[18]
Nadroparin calcium	DMBNKST	Coagulation defect	3B10.0	Approved	[19]
Fondaparinux sodium	DMWS3FH	Deep vein thrombosis	BD71	Approved	[20]
Danaparoid	DM6CLBN	Deep venous clot	BD71	Approved	[21]
Coagulation Factor IX	DM8HBJI	Haemophilia B	3B11.0	Approved	[22]

Drug(s) Targeting Coagulation factor IIa (F2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Argatroban	DMFI46A	Thrombosis	DB61-GB90	Approved	[23]
Pyridoxal Phosphate	DMO2K0J	Malnutrition	5B50-5B71	Approved	[24]
Bivalirudin	DMECRX1	Thrombocytopenia	3B64	Approved	[25]
Ximelegatran	DMU8ANS	Myocardial infarction	BA41-BA43	Approved	[26]
Dabigatran	DMDI6R4	Stroke	8B20	Approved	[27]
Desirudin Recombinant	DM2BTFN	Coagulation defect	3B10.0	Approved	[28]
Human prothrombin complex concentrate	DMPHVQ1	Bleeding disorder	GA20-GA21	Approved	[29]
Lepirudin	DM1I3D5	Thrombocytopenia	3B64	Approved	[30]
Anisindione	DM2C48U	Coagulation defect	3B10.0	Approved	[31]
ATryn antithrombin	DM79Y2T	Multiple sclerosis	8A40	Approved	[32]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Coagulation factor IIa (F2)	TT6L509	THRB_HUMAN	Inhibitor	[1]
Coagulation factor Xa (F10)	TTCIHJA	FA10_HUMAN	Inhibitor	[1]
Plasma kallikrein (KLKB1)	TTMF8H9	KLKB1_HUMAN	Inhibitor	[1]
Tissue factor (F3)	TT38MDJ	TF_HUMAN	Inhibitor	[1]

References

• [1] Novel 3-carboxamide-coumarins as potent and selective FXIIa inhibitors. J Med Chem. 2008 Jun 12;51(11):3077-80.
• [2] FDA Approved Drug Products from FDA Official Website. 2021. Application Number: 761208.
• [3] ImmunoPET of tissue factor expression in triple-negative breast cancer with a radiolabeled antibody Fab fragment. Eur J Nucl Med Mol Imaging. 2015 Jul;42(8):1295-303.
• [4] TETIS study: evaluation of new topical hemostatic agent TT-173 in tooth extraction. Clin Oral Investig. 2016 Jun;20(5):1055-63.
• [5] Clinical pipeline report, company report or official report of Morphotek.
• [6] Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery. Expert Opin Biol Ther. 2008 Aug;8(8):1187-99.
• [7] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [8] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] Clinical pipeline report, company report or official report of KalVista Pharmaceuticals.
• [11] Clinical pipeline report, company report or official report of Oxurion.
• [12] N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38.
• [13] Pfizer. Product Development Pipeline. March 31 2009.
• [14] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [15] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2359).
• [16] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [17] Company report (Portola)
• [18] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [19] Serum zinc concentrations: contamination from laboratory equipment. JPEN J Parenter Enteral Nutr. 1979 May-Jun;3(3):179-81.
• [20] Biochemistry and clinical pharmacology of new anticoagulant agents. Pathophysiol Haemost Thromb. 2002 Sep-Dec;32(5-6):218-24.
• [21] Effect of factor X inhibition on coagulation activation and cytokine induction in human systemic inflammation. J Infect Dis. 2002 Nov 1;186(9):1270-6.
• [22] Haemophilia B: Christmas disease. Expert Opin Pharmacother. 2005 Aug;6(9):1517-24.
• [23] Studies on the different modes of action of the anticoagulant protease inhibitors DX-9065a and Argatroban. I. Effects on thrombin generation. J Biol Chem. 2002 Dec 27;277(52):50439-44.
• [24] New antithrombotic drugs (excluding plasminogen activators. Arch Mal Coeur Vaiss. 2001 Nov;94(11 Suppl):1225-32.
• [25] New anticoagulants. Am Heart J. 2001 Aug;142(2 Suppl):S3-8.
• [26] Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
• [27] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [28] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [29] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2362).
• [30] Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis. Kidney Int Suppl. 1999 Nov;(72):S46-50.
• [31] Anticoagulation with anisindione in a patient with a warfarin-induced skin eruption. Pharmacotherapy. 2003 Apr;23(4):533-6.
• [32] Antithrombin III Utilization in a Large Teaching Hospital. P T. 2013 December; 38(12): 764-767, 779.